Filtered By:
Source: Cancer Control
Vaccination: Cancer Vaccines
This page shows you your search results in order of date. This is page number 6.
Order by Relevance | Date
Total 661 results found since Jan 2013.
Increased neutralization potency and breadth elicited by a SARS-CoV-2 mRNA vaccine forming virus-like particles
Proc Natl Acad Sci U S A. 2023 Jul 18;120(29):e2305896120. doi: 10.1073/pnas.2305896120. Epub 2023 Jul 10.ABSTRACTVaccines have played a fundamental role in the control of infectious diseases. We previously developed a messenger RNA (mRNA) vaccine against HIV-1 that forms virus-like particles (VLPs) through coexpression of the viral envelope with Gag. Here, we applied the same principle to the design of a VLP-forming mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To promote cognate interaction with simian immunodeficiency virus (SIV) Gag, we engineered different chimeric proteins encompa...
Source: Cancer Control - July 10, 2023 Category: Cancer & Oncology Authors: Peng Zhang Samantha Falcone Yaroslav Tsybovsky Mamta Singh Vinay Gopan Huiyi Miao Yuna Seo Denise Rogers Isabella Renzi Yen-Ting Lai Elisabeth Narayanan Guillaume Stewart-Jones Sunny Himansu Andrea Carfi Anthony S Fauci Paolo Lusso Source Type: research
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors
CONCLUSIONS: Our findings would strengthen the recommendation not to change anti-PD-1/PD-L1 treatment plans based on current or future immunization schedules, implying that all these patients should be closely monitored.PMID:37428196 | DOI:10.1007/s00262-023-03489-1
Source: Cancer Control - July 10, 2023 Category: Cancer & Oncology Authors: Fabrizio Nelli Diana Giannarelli Agnese Fabbri Antonella Virtuoso Julio Rodrigo Giron Berrios Eleonora Marrucci Cristina Fiore Marta Schirripa Carlo Signorelli Mario Giovanni Chilelli Francesca Primi Valentina Panichi Giuseppe Topini Maria Assunta Silvest Source Type: research
N-terminal alanine-rich (NTAR) sequences drive precise start codon selection resulting in elevated translation of multiple proteins including ERK1/2
We report the discovery of N-terminal alanine-rich sequences, which we term NTARs, that act in concert with their native 5'-untranslated regions to promote selection of the proper start codon. NTARs also facilitate efficient translation initiation while limiting the production of non-functional polypeptides through leaky scanning. We first identified NTARs in the ERK1/2 kinases, which are among the most important signaling molecules in mammals. Analysis of the human proteome reveals that hundreds of proteins possess NTARs, with housekeeping proteins showing a particularly high prevalence. Our data indicate that several of ...
Source: Cancer Control - July 6, 2023 Category: Cancer & Oncology Authors: Roser Busc à Cercina Onesto Myl ène Egensperger Jacques Pouyss égur Gilles Pag ès Philippe Lenormand Source Type: research
The effectiveness of a religiously framed HPV vaccination message among Christian parents of unvaccinated adolescents in the United States
CONCLUSION: Our findings support the need for equitable messaging regarding HPV vaccination. Faith-based messaging interventions that seek to increase HPV vaccination should be framed to address religious anti-vaccination beliefs.PMID:37401883 | DOI:10.1080/17538068.2023.2171613
Source: Cancer Control - July 4, 2023 Category: Cancer & Oncology Authors: Ayokunle Olagoke Jennifer Hebert-Beirne Brenikki Floyd Rachel Caskey Andrew Boyd Yamil é Molina Source Type: research
Steering and controlling evolution - from bioengineering to fighting pathogens
Nat Rev Genet. 2023 Jul 3. doi: 10.1038/s41576-023-00623-8. Online ahead of print.ABSTRACTControl interventions steer the evolution of molecules, viruses, microorganisms or other cells towards a desired outcome. Applications range from engineering biomolecules and synthetic organisms to drug, therapy and vaccine design against pathogens and cancer. In all these instances, a control system alters the eco-evolutionary trajectory of a target system, inducing new functions or suppressing escape evolution. Here, we synthesize the objectives, mechanisms and dynamics of eco-evolutionary control in different biological systems. We...
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Michael L ässig Ville Mustonen Armita Nourmohammad Source Type: research
Multimodeling approach to evaluating the efficacy of layering pharmaceutical and nonpharmaceutical interventions for influenza pandemics
Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2300590120. doi: 10.1073/pnas.2300590120. Epub 2023 Jul 3.ABSTRACTWhen an influenza pandemic emerges, temporary school closures and antiviral treatment may slow virus spread, reduce the overall disease burden, and provide time for vaccine development, distribution, and administration while keeping a larger portion of the general population infection free. The impact of such measures will depend on the transmissibility and severity of the virus and the timing and extent of their implementation. To provide robust assessments of layered pandemic intervention strategies, the Cente...
Source: Cancer Control - July 3, 2023 Category: Cancer & Oncology Authors: Pragati V Prasad Molly K Steele Carrie Reed Lauren Ancel Meyers Zhanwei Du Remy Pasco Jorge A Alfaro-Murillo Bryan Lewis Srinivasan Venkatramanan James Schlitt Jiangzhuo Chen Mark Orr Mandy L Wilson Stephen Eubank Lijing Wang Matteo Chinazzi Ana Pastore Y Source Type: research
High SARS-CoV-2 seroprevalence in Lagos, Nigeria with robust antibody and cellular immune responses
CONCLUSIONS: These results have important implications for understanding the paradoxically high SARS-CoV-2 infection with low mortality rate in Africa and supports the need to better understand the implications of SARS-CoV-2 cellular immunity.PMID:37388808 | PMC:PMC10289822 | DOI:10.1016/j.jcvp.2023.100156
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Sulaimon Akanmu Bobby Brooke Herrera Beth Chaplin Sade Ogunsola Akin Osibogun Fatima Onawoga Sarah John-Olabode Iorhen E Akase Augustina Nwosu Donald J Hamel Charlotte A Chang Phyllis J Kanki Source Type: research
The Oncolytic herpes simplex virus type-1 (HSV-1) vaccine strain VC2 causes intratumor infiltration of functionally active T cells and inhibition of tumor metastasis and pro-tumor genes VEGF and PDL1 expression in the 4T1/Balb/c mouse model of stage four breast cancer
Conclusion: These results show that VC2 therapy can improve anti-tumor response associated with a better control of tumor metastasis. improve T cell responses and reduce pro-tumor biomarker gene transcription. VC2 holds promise for further development as an oncolytic and immunotherapeutic approach to treat breast and other cancers.PMID:37388243 | PMC:PMC10303929 | DOI:10.3389/fmolb.2023.1199068
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Rafiq Nabi Farhana Musarrat Jose Cesar Menk P Lima Ingeborg M Langohr Vladimir N Chouljenko Konstantin G Kousoulas Source Type: research
Oral Nirmatrelvir and Ritonavir for Covid-19 in Vaccinated, Non-Hospitalized Adults, Ages 18-50 Years
CONCLUSION: NMV-r use in vaccinated adults aged 18-50, especially with serious comorbidities, was associated with reduced all-cause hospital visits, hospitalization, and mortality in the first 30 days of Covid-19 illness. However, NMR-r in patients without significant comorbidities or with only asthma/COPD had no association of benefit. Therefore, identifying high-risk patients should be a priority and avoid over-prescription should be avoided.PMID:37387690 | DOI:10.1093/cid/ciad400
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Jeremy Samuel Faust Ashish Kumar Jui Shah Sumanth Khadke Sourbha S Dani Sarju Ganatra Paul E Sax Source Type: research
Preventive behaviors and behavioral risk factors among gynecologic cancer survivors: Results from the 2020 Behavioral Risk Factor Surveillance System Survey
CONCLUSION: Smoking prevalence among gynecologic cancer survivors is alarmingly high. Intervention studies are needed to identify effective ways to assist gynecologic cancer survivors to quit smoking and refrain from hazardous alcohol consumption. In addition, women with gynecologic malignancies should made aware of the importance of physical activity.PMID:37387412 | DOI:10.1002/cam4.6134
Source: Cancer Control - June 30, 2023 Category: Cancer & Oncology Authors: Steven S Coughlin Biplab Datta Justin Xavier Moore Marlo M Vernon Martha S Tingen Source Type: research
Epidemiological study of vaccination against SARS-CoV-2 and its impact on COVID-19 progression in a cohort of patients in gran Canaria
Conclusions. Cancer, coronary heart disease, and immunosuppressive treatment were associated with increased COVID-19 mortality. More complete vaccination was associated with lower risk of hospital admission or death. Three doses of the SARS-CoV-2 vaccine were highly associated with the prevention of death and hospital admission in all age groups. These findings suggest that COVID-19 vaccination can help bring the pandemic under control.PMID:37366493 | PMC:PMC10288311 | DOI:10.1016/j.vacun.2023.06.005
Source: Cancer Control - June 27, 2023 Category: Cancer & Oncology Authors: Alejandro de Arriba Fern ández Jos é Luis Alonso Bilbao Alberto Espi ñeira Francés Antonio Cabeza Mora Ángela Gutiérrez Pérez Miguel Ángel Díaz Barreiros Source Type: research
Data quality in an HIV vaccine efficacy clinical trial in South Africa: through natural disasters and with discipline
CONCLUSIONS: In the age of infectious and climate disaster risks, trials may benefit from simple study designs and trial-related documents. To optimise protocol adherence, sponsors and sites should consider ongoing training, and routinely review deviation reports with a view to adjusting processes. These data quality lessons may inform future trial design, training and implementation.TRIAL REGISTRATION: HVTN 702 was registered with the South African National Clinical Trials Register (DOH-27-0916-5327) and ClinicalTrials.gov ( NCT02968849 ).PMID:37355583 | DOI:10.1186/s12874-023-01967-9
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Fatima Laher Mookho Malahleha Shelly Ramirez William Brumskine Kennedy Otwombe Zoe Moodie Mary Allen Source Type: research
Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: an open-label, observational phase 4 trial
Lancet Microbe. 2023 Jun 21:S2666-5247(23)00107-6. doi: 10.1016/S2666-5247(23)00107-6. Online ahead of print.ABSTRACTBACKGROUND: Correlates of protection could help to assess the extent to which a person is protected from SARS-CoV-2 infection after vaccination (so-called breakthrough infection). We aimed to clarify associations of antibody and T-cell responses after vaccination against COVID-19 with risk of a SARS-CoV-2 breakthrough infection and whether measurement of these responses enhances risk prediction.METHODS: We did an open-label, phase 4 trial in two community centres in the Schwaz district of the Federal State o...
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Lisa Seekircher Zolt án Bánki Janine Kimpel Annika R össler Helena Sch äfer Barbara Falkensammer David Bante Lukas Forer Sebastian Sch önherr Shieldvacc-2 Study Group Teresa Harthaller Magdalena Sacher Cornelia Ower Lena Tschiderer Hanno Ulmer Floria Source Type: research
Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design
The objectives of the Researching COVID to Enhance Recovery (RECOVER) Multi-site Observational Study of PASC in Adults (RECOVER-Adult) are to: (1) characterize PASC prevalence; (2) characterize the symptoms, organ dysfunction, natural history, and distinct phenotypes of PASC; (3) identify demographic, social and clinical risk factors for PASC onset and recovery; and (4) define the biological mechanisms underlying PASC pathogenesis.METHODS: RECOVER-Adult is a combined prospective/retrospective cohort currently planned to enroll 14,880 adults aged ≥18 years. Eligible participants either must meet WHO criteria for suspected...
Source: Cancer Control - June 23, 2023 Category: Cancer & Oncology Authors: Leora I Horwitz Tanayott Thaweethai Shari B Brosnahan Mine S Cicek Megan L Fitzgerald Jason D Goldman Rachel Hess S L Hodder Vanessa L Jacoby Michael R Jordan Jerry A Krishnan Adeyinka O Laiyemo Torri D Metz Lauren Nichols Rachel E Patzer Anisha Sekar Nor Source Type: research
